Alvotech Petitions FDA To Deny Interchangeability For Rival Stelara Biosimilars
Urges Agency Not To Approve Samsung Bioepis And Sandoz’s Pyzchiva As Interchangeable
Alvotech is calling on the FDA to deny interchangeability for certain ustekinumab biosimilars (Shutterstock) 
